Skip to Main Content

Dehydroepiandrosterone Sulfate (DHEA-Sulfate)

Principle

Dehydroepiandrosterone sulfate (DHEA-S) is a steroid synthesized primarily by the adrenal gland. In tissues containing sulfatase activity, DHEA-S can be converted into free DHEA. Both DHEA and DHEA-S may be further metabolized into active androgens and estrogens.

Serum and plasma DHEA-S concentrations are the highest of all steroids. Levels peak during the third decade of life and decline with age in both sexes. The half-life of DHEA-S (8–10 hours) is significantly longer than that of other androgens (30–60 minutes). Its long half-life and minimal diurnal variation make DHEA-S a useful marker of adrenal androgen production.

Clinical applications include evaluation of Cushing’s syndrome, congenital adrenal hyperplasia, adrenal tumors, and hirsutism. Elevated DHEA-S in hirsute women suggests a virilizing adrenal tumor. Increased DHEA-S may also be seen in polycystic ovary syndrome, indicating adrenal androgen excess.

Specimen Requirements

Specimen

Serum (red-top tube with no additive or serum separator tube, SST)

Collection

Separate serum from clot as soon as possible to prevent hemolysis.

Processing

Separate serum from clot as soon as possible to prevent hemolysis.

Storage and Transport

Store/transport at 15–30°C for ≤8 hours; 2–8°C for ≤48 hours; freeze at ≤ –20°C if delayed. Avoid repeated freeze–thaw cycles.

Unacceptable Specimens

Hemolyzed or unseparated specimens.

Method

Enhanced chemiluminescence

Normal Range

Age Male Female
<1 Month ≤316 15–261
1–6 Months ≤58 ≤74
7–11 Months ≤26 ≤26
1–3 Years ≤15 ≤22
4–6 Years ≤27 ≤34
7–9 Years ≤91 ≤92
10–13 Years ≤138 ≤148
14–17 Years 38–340 37–307
18–21 Years 24–537 51–321
22–30 Years 85–690 18–391
31–40 Years 106–464 23–266
41–50 Years 70–495 19–231
51–60 Years 38–313 8–188
61–70 Years 24–244 12–133
≥71 Years 5–253 7–177

Turnaround Time

3 days

References

  • Meikle AW, Daynes RA, Araneo BA. Adrenal androgen secretion and biologic effects. Endocrinol Metab Clin North Am. 1991;20(2):381–400.
  • Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic DHEA and DHEA-S levels to risk of premenopausal breast cancer. Cancer Res. 1992;52(1):1–4.

Back to Reproductive Immunology